Neoantigen × AI
Daily research signal
№57Brief

Geneos five-year data shows sustained neoantigen immunity in glioma

Today's items show the neoantigen vaccine field stretching across modalities and settings: Geneos reports five-year follow-up supporting sustained immune surveillance and dynamic re-dosing in glioma, while NCI advances a fixed neoantigen viral-vector vaccine into a phase 2 Lynch syndrome interception trial.PR Newswiretrial

Russia's Gamaleya adds a single-patient anecdote for its personalized mRNA program — program progress, not efficacy evidence.Vietnam.vn Underpinning it all, a new allele-specific deep learning predictor targets the false-positive problem that still constrains epitope selection.PubMed

4new stories1 in context
ClinicaltodayNew

Geneos Therapeutics Presents Personalized Neoantigen-Based DNA Therapy That Sustains Anti-tumor Immunity in Brain Cancer Patients and Offers a Path to Dynamic Therapy - PR Newswire

Geneos Therapeutics presented extended follow-up (Abstract CTIM-23, SNO Annual Meeting, presented by Washington University's Tanner Johanns) on two high-grade glioma patients treated with its personalized neoantigen DNA immunotherapy (PIC). A newly diagnosed MGMT-unmethylated glioblastoma patient on the GT-20 trial (NCT04015700) received 19 doses encoding 38 neoantigens over five years and is progression-free five years post-diagnosis, with imaging findings consistent with progression at 1.7, 2.2, and 3 years largely resolving while on PIC alone. The data support the feasibility of sustained immune surveillance and a dynamic therapy model in CNS tumors — an argument for longitudinal re-sequencing and iterative vaccine updates as a differentiator for DNA-based platforms.

news · today · PR Newswire

03

01
ClinicaltodayNew

A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome

NCI is sponsoring a phase 2 trial (NCT07937696, not yet recruiting) testing Nous-209 — man-made copies of neoantigens delivered via viral vectors — to reduce the size of existing 5–15 mm colorectal lesions in Lynch syndrome patients, whose uncorrected genetic errors generate neoantigen-producing cells. The trial moves neoantigen vaccination from treatment into lesion interception, a setting with near-term measurable endpoints and a defined high-risk population. NCI sponsorship is a meaningful institutional validation signal for the non-personalized vaccine approach.

clinicaltrials · today · National Cancer Institute (NCI)
02
ClinicaltodayNew

Russian mRNA cancer vaccine: First patient completes treatment, no new tumors have appeared. - Vietnam.vn

Gamaleya's personalized mRNA vaccine NeoOncovac has completed its first treated patient — a 60-year-old man with stage 3 metastatic melanoma who began treatment in April at the Herzen Cancer Research Institute — with no new tumors on imaging at four-month follow-up and a reported anti-cancer immune response, per scientific director Alexander Gintsburg. This is a single-patient, uncontrolled anecdote with no comparator and no claim of regression of existing disease, so it should be read as program momentum rather than efficacy evidence. Monthly high-resolution CT monitoring continues.

news · today · Vietnam.vn
03
Commercial5 days agoNew

Neoantigen Vaccines Signal A New Arm of Cancer Immunotherapy - Targeted Onc

Parker Institute CEO Karen Knudsen frames neoantigen vaccines as a pivotal new arm of cancer immunotherapy beyond cell-based therapies and checkpoint inhibitors, emphasizing their individual-level specificity. Commentary from a major nonprofit research organization signals growing institutional buy-in that could shape funding and partnership flows toward the platform class.

news · 5 days ago · Targeted Onc

01

Relevant work from earlier we're still surfacing — not today's news.